Teicoplanin

Chemical formula: C₈₈H₉₇Cl₂N₉O₃₃  Molecular mass: 1,879.7 g/mol 

Therapeutic indications

Teicoplanin is indicated for:

Complicated skin and soft tissue infections

Population group: only adolescents (12 years - 18 years old) , adults (18 years old or older)

Soft tissue infection and additionally at least one of
Teicoplanin susceptible species
Teicoplanin susceptible species for which acquired resistance may be a problem

For this indication, competent medicine agencies globally authorize below treatments (click for details):

Infective endocarditis

Population group: only adolescents (12 years - 18 years old) , adults (18 years old or older)

Infective endocarditis and additionally at least one of
Teicoplanin susceptible species
Teicoplanin susceptible species for which acquired resistance may be a problem

For this indication, competent medicine agencies globally authorize below treatments (click for details):

Complicated skin and soft tissue infections, bone and joint, urinary tract, pneumonia, endocarditis

Population group: only newborns (0 - 40 days old) , infants (40 days - 1 year old) , children (1 year - 12 years old)

at least one of
Soft tissue infection
Infective endocarditis
Pneumonia
Urinary tract infectious disease
Infection of bone
Infectious disorder of joint
and additionally at least one of
Teicoplanin susceptible species
Teicoplanin susceptible species for which acquired resistance may be a problem

For this indication, competent medicine agencies globally authorize below treatments (click for details):

Pneumonia

Population group: only adolescents (12 years - 18 years old) , adults (18 years old or older)

Pneumonia and additionally at least one of
Teicoplanin susceptible species
Teicoplanin susceptible species for which acquired resistance may be a problem

For this indication, competent medicine agencies globally authorize below treatments (click for details):

Complicated urinary tract infections

Population group: only adolescents (12 years - 18 years old) , adults (18 years old or older)

Urinary tract infectious disease and additionally at least one of
Teicoplanin susceptible species
Teicoplanin susceptible species for which acquired resistance may be a problem

For this indication, competent medicine agencies globally authorize below treatments (click for details):

Bone and joint infections

Population group: only adolescents (12 years - 18 years old) , adults (18 years old or older)

at least one of
Infection of bone
Infectious disorder of joint
and additionally at least one of
Teicoplanin susceptible species
Teicoplanin susceptible species for which acquired resistance may be a problem

For this indication, competent medicine agencies globally authorize below treatments (click for details):

Clostridium difficile infection

Population group: only adolescents (12 years - 18 years old) , adults (18 years old or older)

Teicoplanin is also indicated as an alternative oral treatment for Clostridium difficile infection-associated diarrhoea and colitis.

For this indication, competent medicine agencies globally authorize below treatments (click for details):

Contraindications

Teicoplanin is contraindicated in the following cases:

Hypersensitivity to teicoplanin

Teicoplanin allergy

Get recommendations

Factors such as age, gender, and health history are evaluated to create a personalized medication regimen.

Ask the Reasoner

Related medicines

Summary of Product Characteristics (SPC) 2019: TARGOCID Powder for solution for injection, infusion or oral solution
< Previous: Overview
Next: Precautions >

© All content on this website, including data entry, data processing, decision support tools, "RxReasoner" logo and graphics, is the intellectual property of RxReasoner and is protected by copyright laws. Unauthorized reproduction or distribution of any part of this content without explicit written permission from RxReasoner is strictly prohibited. Any third-party content used on this site is acknowledged and utilized under fair use principles.

⇈